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Estrogen receptor-a (ER) is the driving transcription
factor in most breast cancers, and its associated
proteins can influence drug response, but direct
methods for identifying interacting proteins have
been limited. We purified endogenous ER using an
approach termed RIME (rapid immunoprecipitation
mass spectrometry of endogenous proteins) and
discovered the interactome under agonist- and
antagonist-liganded conditions in breast cancer
cells, revealing transcriptional networks in breast
cancer. The most estrogen-enriched ER interactor
is GREB1, a potential clinical biomarker with no
known function. GREB1 is shown to be a chro-
matin-bound ER coactivator and is essential for
ER-mediated transcription, because it stabilizes
interactions between ER and additional cofactors.
We show a GREB1-ER interaction in three xenograft
tumors, and using a directed protein-protein ap-
proach, we find GREB1-ER interactions in half
of ER+ primary breast cancers. This finding is sup-
ported by histological expression of GREB1, which
shows that GREB1 is expressed in half of ER+
cancers, and predicts good clinical outcome. These
findings reveal an unexpected role for GREB1 as an
estrogen-specific ER cofactor that is expressed in
drug-sensitive contexts.INTRODUCTION
Estrogen receptor-a (ER) is the key transcription factor that
drives gene expression programs in ER+ luminal breast cancers342 Cell Reports 3, 342–349, February 21, 2013 ª2013 The Authors(Ali and Coombes, 2002). ER+ breast cancers constitute the
majority of breast tumors, and these are generally treated with
ER antagonists, although clinical response varies significantly
(Ali and Coombes, 2002). ER-mediated transcription is deter-
mined by the associated cofactors and interacting transcription
factors that form the ER complex (Shang et al., 2000). Increased
levels of ER-associated cofactors have been shown to correlate
and contribute to drug resistance (Anzick et al., 1997; Torres-
Arzayus et al., 2004), highlighting the importance of these cofac-
tors in mediating ER transcriptional activity. Despite the fact that
there are many known ER-associated factors (Me´tivier et al.,
2003; Okada et al., 2008), it is clear that critical regulators are still
being identified, as highlighted by the recent discovery of ER-
associated pioneer factors such as FoxA1, PBX-1, and AP-2g
(Carroll et al., 2005; Magnani et al., 2011; Tan et al., 2011), via
enrichment of their DNA consensus sequence within ER binding
domains. Direct experimental approaches for finding interacting
proteins usually involve exogenous-tagged methods or require
very large-scale cell line culture (Malovannaya et al., 2010,
2011; Selbach and Mann, 2006) and are nonexistent in primary
tissue.
We develop an endogenous protocol for systematic analysis
of protein-protein interactions and protein-DNA binding events.
We have combined several robust methods including formalde-
hyde crosslinking and on-bead digestion, permitting rapid and
sensitive purification of endogenous-interacting proteins. Cross-
linking with formaldehyde is well established in chromatin immu-
noprecipitation (ChIP) and tissue fixation. Its size (2 A˚) and
ability to permeate membranes of intact living cells have two
important implications: only amino acids in close proximity
(2.3–2.7 A˚) will be crosslinked, and nonspecific interactions by
abundant proteins are minimized by the cells own architecture
(Sutherland et al., 2008). This approach, termed RIME (rapid
immunoprecipitation mass spectrometry of endogenous pro-
teins), identifies ER-associated transcriptional networks and
ligand-specific interactions.
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Figure 1. ER RIME Purification of Associ-
ated Proteins
(A) ER RIME was conducted in MCF-7 breast
cancer cells. The graphical plot (termed MS-ARC)
shows ER-associated proteins. Nonspecific inter-
actions (identified from multiple IgG control repli-
cates) have been removed. The ER-associated
proteins are clustered according to molecular
function, and the length of the line represents the
Mascot score.
(B) Peptide coverage (highlighted in green) of ER
and additional identified interacting proteins.
(C) Hormone-deprived MCF-7 cells were labeled
with ‘‘heavy’’ or ‘‘light’’ SILAC isotopes, treated
with estrogen or tamoxifen, and ER RIME was
conducted. Two replicates were conducted and
shown are peptides found in both replicates. The
axis represents log10 scale. The ER-DNA-inter-
acting complex, including putative pioneer factors,
is highlighted in blue text. GREB1 was the most
estrogen-induced ER-interacting protein based on
SILAC ratio.
Additional relevant information is provided in
Figures S1, S2–S5, and Table S1.GREB1 is shown to be the most estrogen-specific ER interac-
tor, and endogenous associations between ER, GREB1, and
additional factors are verified both in vitro and in vivo. Very little
is known about the function of GREB1, but GREB1 is one of the
highest estrogen-induced genes (Ghosh et al., 2000) and corre-
lates well with changes in ER activity following breast cancer
treatment (Dunbier et al., 2010). In addition, it is known that
GREB1 is required for growth of ER+ breast cancer cells (Rae
et al., 2005), and overexpression can increase colony formation
(Liu et al., 2012). However, it was not knownwhat themechanism
is that allows GREB1 to mediate these effects. We now provide
functional insight into how GREB1 mediates ER transcriptional
activity and show that it is an independent predictor of clinical
outcome in patients with breast cancer.
RESULTS
Purification of ER-Associated Proteins Using RIME
Endogenous ERwas purified from 13 107 asynchronousMCF-7
breast cancer cells using RIME. The validation of the method is
provided in Figure S1. In addition, RIME has been successfully
utilized for purification of numerous other factors (an additional
example [E2F4] is shown in Figure S2). We only consideredCell Reports 3, 342–349,ER-associated proteins that occurred in
three out of three independent replicates
and excluded any protein that appeared
in any one of five IgG control RIME. This
resulted in 108 ER-associated proteins
(Figure 1A). The most confident protein
identified from the ER RIME was ER.
Also included within the ER interac-
tion list are recently characterized ER
pioneer factors FoxA1, TLE1, and AP2-g
(Carroll et al., 2005; Holmes et al., 2012;Tan et al., 2011), putative pioneer factors such as GATA3 (Theo-
dorou et al., 2013), known cofactors including RIP140 (NRIP1),
AIB1 (NCOA3), p300, CBP, and CARM1, plus RAR family
members that were recently implicated as ER-associated
protein (Hua et al., 2009; Ross-Innes et al., 2010). Peptide
coverage of specific associated proteins is shown in Figure 1B.
We also find a number of repressors, including N-CoR, SMRT,
and HDAC2, which are known to be recruited with estrogen-
ER to repressed genes such as cyclin G2 (Stossi et al., 2006).
A full list of ER-interacting proteins is provided in Figure S3.
More than 25% of the 108 ER-associated proteins were previ-
ously validated ER interactors (Figure S3). In addition, six pre-
viously uncharacterized ER-associated proteins were selected
for validation by standard coimmunoprecipitation (coIP) (no
crosslinking) and ChIP sequencing (ChIP-seq) in MCF-7 cells
(Figure S4).
ER RIME was repeated in asynchronous SILAC-labeled cells
following 3 hr of estrogen treatment or 3 hr of treatment with
tamoxifen, the clinical ER antagonist. Two biological replicates
were conducted. A number of proteins were predominantly
bound with ER following treatment of either the agonist
(estrogen) or the antagonist (tamoxifen) (Figure 1C). The core
ER-DNA complex, composed of ER and the putative pioneerFebruary 21, 2013 ª2013 The Authors 343
factors FoxA1, GATA3, and TLE1, is found under both ligand
conditions (Figure 1C). GREB1 was the most markedly induced
estrogen-ER-interacting protein, based on SILAC ratio. Informa-
tion on the spectra is provided in Figure S5. These data support
the hypothesis that GREB1 is an ER-associated protein only
recruited under estrogenic conditions.
GREB1 Is a Chromatin-Bound Protein Required for ER-
Mediated Transcription
GREB1 is a highly estrogen-induced gene (Ghosh et al.,
2000) with almost no known function. ChIP-seq of GREB1
in estrogen-rich asynchronous MCF-7 cells revealed 8,420
GREB1 binding regions that occurred in two independent repli-
cates (Figure 2A). Almost all (95%) of the GREB1 binding
events were shared by ER (Robinson et al., 2011) (Figure 2A).
GREB1 binding was dependent on ER because pretreatment
with ICI 182780 (an ER degrader) reduced GREB1 binding, as
assessed by ChIP-seq (Figure 2B), despite GREB1 protein levels
remaining the same at this short treatment time point (Figure S6).
The GREB1 binding to ER cis-regulatory elements was validated
by standard ChIP (Figure S6) and with an independent antibody
(Figure S6). The interaction between ER and GREB1 was further
validated by performing genome-wide ER and GREB1 re-ChIP-
seq, confirming global co-occupancy of these two proteins to
the same genomic loci (data not shown).
Because GREB1 was found to be the most estrogen-enriched
ER interactor, we investigated the functional role of this poorly
understood protein. MCF-7 cells were hormone deprived, trans-
fected with control small interfering RNA (siRNA) or a siRNA to
GREB1 (Figure 2C), and treated with estrogen or vehicle control
for 6 hr for microarray analysis. Differential gene expression anal-
ysis revealed 739 genes that were estrogen regulated (p < 0.01),
and almost half of these were no longer differentially expressed
when GREB1 was specifically silenced (Figure 2D). In addition,
silencing of GREB1 significantly impaired the ability of MCF7
breast cancer cells to form colonies in soft agar, suggesting
that it is required for their transformed phenotype (Figure 2E).
We overlapped GREB1 binding events with p300 or CBP
binding events previously mapped in MCF-7 cells (Zwart et al.,
2011) and found that most GREB1 binding events were also
co-occupied by the coactivators p300 and CBP (Figure 2F).
GREB1 possesses two LXXLL motifs, used by cofactors to in-
teract with nuclear receptors (Heery et al., 1997), and as such,
we assessed whether GREB1 may be involved in modulating
binding between p300/CBP and ER. GREB1 was silenced with
siRNA, and ChIP of ER, p300, and CBP was assessed at shared
cis-regulatory elements. Specific silencing of GREB1 did not
affect ER binding (data not shown), but p300 and CBP binding
was decreased on all the tested regions (Figure 2F), suggesting
that GREB1 may stabilize the interaction with the classic, enzy-
matically active coactivators at specific ER binding regions.
Purification of Associated Proteins In Vivo
ER RIME was conducted from three independent MCF-7 xeno-
graft tumors, implanted in immunocompromised mice (data
not shown). In all three xenografts, ER-GREB1 interactions
were observed (relative to matched IgG controls) (Figure S7),
providing evidence that ER-GREB1 associations occur in solid344 Cell Reports 3, 342–349, February 21, 2013 ª2013 The Authorstumor models. In addition to proteomic analysis, ER and
GREB1 ChIP-seq was conducted on one of the MCF7 xeno-
grafts. Unexpectedly, MCF7 cells grown as a xenograft have
a different ER binding profile compared to MCF7 cell growth
in vitro (Figure 3A). In the xenografts, ER and GREB1 binding
overlapped significantly, confirming that GREB1 binding paral-
leled the ER-DNA interactions observed in vivo (Figures 3B and
3C). We recently established a method for transcription factor
mapping in primary human breast cancer samples (Ross-Innes
et al., 2012), enabling genomic interrogation of ER binding
properties. We sought to establish a method for protein-protein
assessment in primary human tumors, to complement
the genomic mapping approaches with proteomic analyses.
Because these primary tumors were very small, potentially
degraded, and heterogeneous, we opted for a targeted ap-
proach by coupling RIME with selective reaction monitoring
(RIME-SRM), a method for sensitive and quantitative assess-
ment of specific peptides of interest. A schematic of the
approach taken is shown in Figure 3D. Seven primary frozen
breast cancers were used, including six ER+ tumors and one
ER control tumor (tumor details are provided in Figure S7).
Each tumor was crosslinked and split into ER or IgG RIME-
SRM. We assessed multiple peptides that represent ER or
some of its interactors identified from the cell line experiments,
including GREB1, RXRa, TLE1, CBP, p300, and NRIP1. The
data represent the average of all peptides for a specific protein
(all peptides are provided in Figure S8), and the enrichment
was normalized to the matched IgG control. We could success-
fully identify ER in all six ER+ tumors, but not the ER tumor
(Figures 3E and S7). Interestingly, we could also find several
ER-interacting proteins in some of the ER+ tumors (Figure 3E).
We confirmed the identity of peptide precursors from tumor
lysates by fragmentation (MS/MS) using a parallel platform (AB
Sciex 5500MS) (data not shown). GREB1-ER interactions were
not found in the ER tumor or in any of the IgG controls and
were observed in three out of the six ER RIME-SRMs from ER+
tumors (Figure 3E), suggesting that not all ER+ tumors have
ER-GREB1 interactions.
GREB1 Expression in Breast Cancer
Given the observation that ER-GREB1 interactions could be
detected in three out of six ER+ breast cancers by ER RIME-
SRM (Figure 3E), we assessed GREB1 expression in a larger
cohort (n = 419) of patients with breast cancer by immunohisto-
chemistry. An antibody for GREB1 was assessed in cell lines
(Figure S9), and examples of GREB1 staining are shown in Fig-
ure 4A. This antibody has been previously validated for immuno-
histochemistry (Hnatyszyn et al., 2010). GREB1 expression was
seen in 46.0% of all breast cancers, and of these, 96.3% were
ER+ breast cancers (Figure 4B), implying that GREB1 expression
is mostly limited to ER+ disease. Of all ER+ breast cancers, 55%
were GREB1 positive, slightly more than the 40% previously
observed by Hnatyszyn et al. (2010). Although GREB1 is an
estrogen-induced gene, and GREB1 expression is limited to
ER+ cancers, ER mRNA levels did not increase with increasing
levels of GREB1 mRNA levels (Figure S9). Within ER+ breast
cancers, GREB1 positivity (Allred >2) correlated with a good clin-
ical outcome (Figure 4C). Although GREB1 is estrogen induced,
Figure 2. GREB1 Is an Estrogen-Mediated ER-Interacting Protein Required for ER Function
(A) Venn diagram showing overlap of GREB1 binding events and ER binding events, as determined by ChIP-seq. Almost all GREB1 binding events are shared
with ER.
(B) ER ChIP-seq was conducted in asynchronous MCF-7 cells. GREB1 ChIP-seq was conducted in asynchronous cells treated with control or ICI 182780 (an ER
downregulator). An example of a binding region is shown.
(C) MCF-7 cells were transfected with siControl or siGREB1, and western blotting confirmed effective knockdown of GREB1.
(D) Hormone-deprived MCF-7 cells were transfected with siControl or siGREB1 (four replicates) and treated with vehicle or estrogen for 6 hr. Microarray analysis
was conducted, and estrogen-mediated differential gene changes (in siControl conditions) were determined. The heatmap represents all genes selected as
differentially expressed following estrogen treatment relative to vehicle, in either siControl or siGREB1-transfected cells.
(E) MCF-7 cells were transfected with siControl or siGREB1, and soft agar assays were conducted. **p < 0.001, Student’s t test. The error bars represent SD.
(F) Overlap of GREB1 binding with the coactivators p300 and CBP. MCF-7 cells were transfected with siControl or siGREB1, and p300 or CBP ChIP was
performed followed by real-time PCR of known ER regulatory regions. In the absence of GREB1, p300 and CBP coactivators cannot bind to enhancer elements.
The error bars represent SD.
Additional relevant information is provided in Figure S6.
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Figure 3. ER and GREB1 Interactions in Solid Tumors
(A) MCF7 cells were implanted into immunocompromised mice, and the xenografts were removed for ER and GREB1 ChIP-seq. Overlap in ER binding, as
determined by ChIP-seq from the MCF7 cell line grown in vitro and as a xenograft. The growth of MCF7 cells as xenografts results in altered ER binding, when
compared to MCF7 cells grown in vitro.
(B) Heatmap showing binding signal intensity of ER and GREB1 from a xenograft.
(C) Example of common ER and GREB1 binding events in a MCF7 xenograft.
(D) Establishment of RIME in clinical samples. Schematic representation of the ERRIME-SRMprotocol used for assessing protein interactions in clinical samples.
Frozen intact breast tumors were crosslinked, and nuclei were collected. Each sample was split into an ER RIME or IgG RIME and subjected to SRM to quantify
specific peptides representing proteins of interest.
(E) ER interactions from six ER+ and one ER tumor. Each tumor was split, and ER RIME or IgG RIME was conducted. SRM was used to identify the presence of
specific peptides that were quantified relative to matched IgG control RIME. Where multiple peptides for a protein were identified, the average was taken. The
peptide information can be found in Figure S8. All enrichments are shown relative to the matched IgG control. N/D, not determined.
Additional relevant information is provided in Figures S7 and S8.this correlation with good outcome may also reflect the func-
tional role of GREB1 as a component of the ER complex. In
support of this, GREB1was found to be a prognostic factor inde-
pendent of the Nottingham prognostic index (NPI) (multivariate
model GREB1 HR = 0.49 [0.26–0.90], p = 0.021; NPI HR = 2.3
[1.7–3.1], p < 0.001) (Figure S9), and in combination with the346 Cell Reports 3, 342–349, February 21, 2013 ª2013 The Authorsclassic prognostic marker PR, GREB1 predicted an additive
clinical benefit, when compared to PR alone (Figure S9).
These findings place GREB1 as a key estrogen-specific ER-
associated protein, where it is functionally linked with the tran-
scriptional output of the ER complex. We observed that
GREB1 is not expressed in a tamoxifen-resistant (Tam-R) breast
A C
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Figure 4. GREB1 Immunohistochemistry in Breast Cancer
(A) Examples of GREB1 staining.
(B) Table representing the number of ER or GREB1-expressing breast cancers.
(C) Kaplan-Meier curve representing clinical outcome relative to GREB1 expression in 338 ER+ cases (HR estimate frommultivariate analysis). An Allred score of
2 was used as a cut point for GREB1 expression.
Additional relevant information is provided in Figures S9 and S10.cancer model (Figure S10), but interestingly, re-expression of
GREB1 in these Tam-R cells results in decreased cell growth
in the presence of tamoxifen. As such, there may be pressure
to inactivate or downregulate GREB1 in endocrine-resistant
cells, potentially explaining why GREB1 expression is restricted
to the 50% of ER+ breast cancer with a good clinical outcome.
DISCUSSION
We have established a rapid protocol for the identification of
endogenous-interacting proteins from limited starting material,
which enables assessment of endogenous protein interactions
in tumormaterial. By applying RIME to ER, themajor driving tran-
scription factor in luminal breast cancer, we have identified
protein networks and functional components of this transcription
complex. These include unexpected transcriptional associations
between ER and COUP-TFII (COT2), KLF4, TLE3, and GREB1
(Figure S4). In addition to ER, we have successfully used this
approach to identify associated complexes for numerous tran-
scription factors. An additional example is shown in Figure S2,
where E2F4 is purified, and the components of the core E2F4
complex are found by RIME in two independent treatment condi-
tions. Our approach provides a cost-effective, sensitive, and
rapid method for discovery of endogenous-interacting proteins.
We exploit the size and permeability of formaldehyde to preserve
bona fide protein-protein interactions, avoiding nonspecific
interactions that would be anticipated in any postlysis proce-
dure. Furthermore, the low-affinity interactions between protein
constituents of transcription factor complexes (interactions
with rapid on-off rates) that would in any other protocol be
missed with even moderate wash stringencies are maintained
using RIME. This is further controlled for by the use of parallel IgG
controls in all experiments and quantitative SILAC approaches toCconfirm specificity. It is also possible that adjacent transcription
complexes that occupy similar DNA binding domains may be
crosslinked, yet digestion of DNA did not greatly affect the ER in-
teractome identified (Figure S1). The sensitivity of RIME from
limited material enables directed approaches for identification
of protein-protein interactions in primarymaterial, such as breast
cancer tissue used in this study.
The most confident estrogen-enriched ER-associated protein
discovered using RIME was the poorly characterized protein
GREB1, a gene with little known function. The interaction
between ER and GREB1 was observed in cell lines, xenograft
tumors, and in several primary human ER+ breast cancer
samples. We show that GREB1 is recruited with ER to transcrip-
tionally active cis-regulatory regions, where it functions as an
essential factor, stabilizing associations with additional cofac-
tors. This is of particular significance given the potential of
GREB1 as a clinical biomarker (Dunbier et al., 2010). Our findings
suggest that GREB1 expression functions as both a readout of
ER transcriptional activity and as a contributing factor to that
transcriptional potential. Interestingly, GREB1 has been shown
to be important for growth of ER+ breast cancer cells (Rae
et al., 2005) and AR+ prostate cancer cells (Rae et al., 2006),
suggesting that it might also be involved in AR function in the
prostate cancer.
Our observations suggest that GREB1 is expressed in half of
ER+ tumors, where it correlates with positive clinical outcome
(Figure 4C). In this subset of ER+ cancers, GREB1 is induced
by the ER complex and is functionally linked with ER transcrip-
tional activity. The absence of GREB1 in the remaining 50% of
ER+ breast cancer (Figure 4B) may reflect a nonfunctional ER
complex, where GREB1 is no longer ER induced. Our data would
suggest (Figure S10) that GREB1 loss may be a contributing
factor to the changes in hormonal responses and acquisition ofell Reports 3, 342–349, February 21, 2013 ª2013 The Authors 347
antiestrogen resistance. This is supported by the observation
that GREB1 expression is downregulated in multiple endo-
crine-resistant cell line models (McCune et al., 2010; Oyama
et al., 2011; Shen et al., 2011) (Figure S10) and that re-expression
of GREB1 results in abrogation of the tamoxifen resistance
(Figure S10). In drug-sensitive cells, GREB1 functions as a
contributor toward a functional ER complex, whereas in drug-
resistant cells, where tamoxifen-ER complex mediates cell
growth, GREB1 is inhibitory. Given the findings that GREB1 is
the least tamoxifen-enriched ER-associated protein (Figure 1C),
tamoxifen-liganded ER complex may acquire dependence on
other upregulated cofactors and may not be able to drive gene
expression in the presence of GREB1. Although it is currently
unclear why GREB1 needs to be downregulated for acquisi-
tion of endocrine resistance, our findings place GREB1 as one
of the central estrogen-specific ER cofactors, where it functions
to mediate interactions between the ER and additional proteins.
EXPERIMENTAL PROCEDURES
Detailed methods are available in Extended Experimental Procedures. All
animal work and human tissue work were performed with the appropriate
ethics, as described in Extended Experimental Procedures.
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